Tom 15, Nr 1 (2020)
Artykuł przeglądowy
Opublikowany online: 2020-02-28
Wyświetlenia strony
510
Wyświetlenia/pobrania artykułu
471
A fresh perspective on anticoagulant therapy in patients with cancer in the era of NOAC
Folia Cardiologica 2020;15(1):27-33.
Streszczenie
Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent years, oncological patients have been given heparin and vitamin K antagonists. Nowadays, non-vitamin K antagonist oral anticoagulants (NOAC) are becoming increasingly widely used. Based on the current state of knowledge, NOAC drugs can be used in anticoagulant treatment of cancer patients with caution, i.e. after assessing the bleeding risk and a risk-benefit analysis of anticoagulant therapy, as well as of the drug interactions between oncological drugs and the NOAC group.
Słowa kluczowe: canceranticoagulant treatmentnon-vitamin K antagonist oral anticoagulants
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)